Material Event Form 8 K

Item 8.01. Other Events.

As previously disclosed, on November 19, 2024, Estrella Immunopharma, Inc. (the "Company") received a notification letter (the "Stockholders' Equity Requirement Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). On December 11, 2024, the Company received a notification letter from Nasdaq stating that for the last 10 consecutive business days, from November 25, 2024 to December 10, 2024, the Company's market value of listed securities has been $35,000,000 or greater. Accordingly, the Company has regained compliance with the Stockholders' Equity Requirement, and this matter is now closed.

Additionally, as previously disclosed, on November 19, 2024, the Company received a notification letter (the "Minimum Bid Price Deficiency Notice") from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days (the "Minimum Bid Price Requirement"). On December 11, 2024, the Company received a notification letter from Nasdaq stating that for the last 10 consecutive business days, from November 25, 2024 to December 10, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and this matter is now closed.